Maybe, but I can't see any reason why he could not have explained that to shareholders.
Ann: SCENESSE European Orphan Drug Designation for VP, page-12
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.40 |
Change
-1.110(7.16%) |
Mkt cap ! $727.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.74 | $14.23 | $2.975M | 201.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9 | $14.37 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.40 | 290 | 15 |
View Market Depth
| Last trade - 13.07pm 09/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |